Table 1 Patient characteristics at baseline in the randomized trial
Control N = 73 (%) | Intervention N = 73 (%) | P-values | |
|---|---|---|---|
Random assignment 73 | |||
Ipilimunab | 3 (4) | 4 (6) | 0.956 |
Pembrolizumab | 36 (49) | 38 (52) | |
Nivolumab | 13 (18) | 11 (15) | |
Ipilimumab+Nivolumab | 21 (29) | 20 (28) | |
Age | |||
Median (range) | 66 (32; 83) | 66 (34; 87) | 0.619 |
Sex | |||
Male | 43 (59) | 35 (48) | 0.184 |
Female | 30 (41) | 38 (52) | |
ECOG Performance status | |||
0 | 52 (72) | 49 (69) | 0.582 |
1 | 19 (26) | 19 (27) | |
2 | 1 (1) | 3 (4) | |
Disease stage | |||
Stage III | 12 (16) | 10 (14) | 0.818 |
Stage IV | 61 (84) | 63 (86) | |
Line of therapy | |||
Adjuvant | 13 (18) | 11 (15) | 0.841 |
1st line | 52 (71) | 52 (71) | |
2nd line | 6 (8) | 6 (8) | |
3rd line | 2 (3) | 4 (5) | |
Lactate dehydrogenase | |||
Normal | 51 (76) | 46 (69) | 0.334 |
Elevated | 16 (24) | 21 (31) | |
BRAF status | |||
Mutated | 31 (42) | 32 (44) | 0.710 |
Wild type | 30 (41) | 27 (37) | |
Unknown | 12 (16) | 14 (19) | |
Experience with electronic devices | |||
None | 0 (0) | 3 (6) | 0.232 |
A little | 16 (38) | 15 (32) | |
A lot | 26 (62) | 29 (62) | |
Educational level | |||
Primary/lower sec. | 16 (23) | 19 (28) | 0.731 |
Upper secondary | 2 (3) | 3 (5) | |
Short cycle tertiary | 15 (22) | 18 (27) | |
Bachelor | 30 (43) | 23 (34) | |
Master | 6 (9) | 4 (6) | |